Table 2.
Field‐test sample characteristics
| Characteristic | n (%) |
|---|---|
| Gender | |
| Male | 135 (54.0) |
| Female | 115 (46.0) |
| Current age (years) | |
| 15–17 | 134 (53.6) |
| 18–20 | 62 (24.8) |
| 21–23 | 42 (16.8) |
| 24–26 | 12 (4.8) |
| Parent's marital status | |
| Married/Common‐law | 176 (70.4) |
| Separated/divorced | 49 (19.6) |
| Widowed/single/never married | 20 (8.0) |
| Missing | 5 (2.0) |
| Ethnicity | |
| Caucasian | 181 (72.4) |
| Other | 65 (26.0) |
| Missing | 4 (1.6) |
| Cancer type | |
| Leukemia | 100 |
| ALL | 86 (86.0) |
| AML | 14 (14.0) |
| Lymphoma | 55 |
| Hodgkins | 25 (45.4) |
| Non‐Hodgkins | 30 (54.6) |
| CNS tumours | 15 |
| Astrocytoma | 4 (26.7) |
| Glioma | 3 (20.0) |
| Clival chordoma | 1 (6.6) |
| Medulloblastoma | 3 (20.0) |
| Other | 4 (26.7) |
| Embryonal tumours | 20 |
| Neuroblastoma | 10 (50.0) |
| Hepatoblastoma | 6 (30.0) |
| Germ cell tumour | 4 (20.0) |
| Renal tumours | 26 |
| Wilms' tumour | 26 (100) |
| Sarcoma | 34 |
| Clear cell sarcoma | 1 (2.9) |
| Rhabdomyosarcoma | 12 (35.3) |
| Ewing's sarcoma | 10 (29.5) |
| Oesteogenic sarcoma | 11 (32.3) |
| Age at diagnosis (years) | |
| 0–4 | 110 (44.0) |
| 5–12 | 93 (37.2) |
| 13–17 | 47 (18.8) |
| Relapse status | |
| Did not relapse | 232 (92.8) |
| Relapsed at least once | 18 (7.2) |
| Treatments | |
| Chemotherapy | 241 (96.4) |
| Radiation therapy | 116 (46.4) |
| Surgery | 92 (36.8) |
| Transplant | 20 (8.0) |
| Years since diagnosis | |
| 0–8 | 90 (36.0) |
| 9–16 | 126 (50.4) |
| 17–26 | 32 (12.8) |
| Missing | 2 (0.8) |
| Transition status | |
| Pre | 168 (67.2) |
| Post | 82 (32.8) |
| Hospital | |
| A | 134 (53.6) |
| B | 87 (34.8) |
| C | 29 (11.6) |